Agilent Technologies vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Santa Clara analytical instruments (NYSE: A) at $6.95B FY2025 revenue; Q4 +9.4% recovery from pharma destocking, LC-MS/gas chromatography leader for drug dev and food safety competing with Waters and Thermo Fisher.
About
Agilent Technologies, Inc. is a Santa Clara, California-based life sciences, diagnostics, and applied chemical analysis instruments company — publicly traded on the New York Stock Exchange (NYSE: A) as an S&P 500 Health Care component — designing, manufacturing, and supporting analytical instruments, consumables, software, and services for pharmaceutical, biopharmaceutical, food safety, environmental, clinical, and academic laboratory applications through approximately 17,000 employees worldwide. In fiscal year 2025 (ending October 2025), Agilent reported full-year revenue of $6.95 billion, with Q4 FY2025 revenue of $1.86 billion (+9.4% reported, +7.2% core growth) — accelerating from the prior year's market correction when the pharmaceutical and biopharma industry destocked lab consumables following the COVID-era inventory surge. The Life Sciences and Diagnostics Markets Group delivered Q4 FY2025 revenue of $755 million (+15% reported, +11% core), reflecting a robust recovery in pharmaceutical R&D laboratory spending. Founded in 1999 as a spinoff from Hewlett-Packard's analytical instruments division (carrying forward HP's tradition of precision measurement instruments dating to 1939), Agilent is organized around three segments: Life Sciences & Applied Markets (liquid chromatography, mass spectrometry, gas chromatography systems for drug development and food/environmental testing), Diagnostics & Genomics (pathology reagents, next-generation sequencing, FISH probes for cancer diagnostics), and Agilent CrossLab (instrument services, calibration, laboratory informatics, and consumables replacement).
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.